Dimensional Fund Advisors
CTMX icon

Dimensional Fund Advisors’s CytomX Therapeutics CTMX Stock Holding History

Dimensional Fund Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.98M Sell
1,860,290
-70,630
-4% -$270K ﹤0.01% 2440
2026
Q1 		$9.07M Buy
1,930,920
+641,264
+50% +$3.25M ﹤0.01% 2284
2025
Q4 		$5.49M Buy
1,289,656
+838,528
+186% +$3.19M ﹤0.01% 2503
2025
Q3 		$1.44M Buy
451,128
+267,962
+146% +$604K ﹤0.01% 2835
2025
Q2 		$416K Buy
+183,166
New +$295K ﹤0.01% 3022
2023
Q3 		– Sell
-35,865
Closed -$61.7K – 3475
2023
Q2 		$61.7K Sell
35,865
-120,591
-77% -$200K ﹤0.01% 3387
2023
Q1 		$236K Buy
+156,456
New +$354K ﹤0.01% 3168
2022
Q3 		$262K Sell
180,580
-216,661
-55% -$333K ﹤0.01% 3190
2022
Q2 		$727K Sell
397,241
-411,899
-51% -$789K ﹤0.01% 2984
2022
Q1 		$2.16M Buy
809,140
+287,113
+55% +$1.1M ﹤0.01% 2808
2021
Q4 		$2.26M Buy
522,027
+198,998
+62% +$1.17M ﹤0.01% 2814
2021
Q3 		$1.64M Sell
323,029
-311,364
-49% -$1.67M ﹤0.01% 2906
2021
Q2 		$4.02M Buy
634,393
+119,342
+23% +$929K ﹤0.01% 2668
2021
Q1 		$3.98M Sell
515,051
-38,853
-7% -$308K ﹤0.01% 2649
2020
Q4 		$3.63M Sell
553,904
-16,700
-3% -$119K ﹤0.01% 2633
2020
Q3 		$3.79M Hold
570,604
– – ﹤0.01% 2539
2020
Q2 		$4.75M Sell
570,604
-23,063
-4% -$214K ﹤0.01% 2492
2020
Q1 		$4.55M Buy
593,667
+24,103
+4% +$168K ﹤0.01% 2449
2019
Q4 		$4.73M Buy
569,564
+162,919
+40% +$1.1M ﹤0.01% 2627
2019
Q3 		$3M Buy
406,645
+57,451
+16% +$567K ﹤0.01% 2759
2019
Q2 		$3.92M Buy
349,194
+208,619
+148% +$2.19M ﹤0.01% 2720
2019
Q1 		$1.51M Buy
140,575
+95,460
+212% +$1.41M ﹤0.01% 2949
2018
Q4 		$681K Buy
+45,115
New +$669K ﹤0.01% 3098

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Dimensional Fund Advisors's CTMX Position: Q2 2026 in Review

Dimensional Fund Advisors reduced its CytomX Therapeutics (CTMX) stake by 3.7% in Q2 2026, selling an estimated $270K and leaving 1,860,290 shares worth $6.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2440.

Dimensional Fund Advisors first reported a position in CTMX in Q4 2018 and has held it in 23 quarters since. The position peaked at $9.07M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Dimensional Fund Advisors held 1,860,290 shares of CytomX Therapeutics worth $6.98M as of Q2 2026.
  • Dimensional Fund Advisors sold 70,630 CytomX Therapeutics shares in Q2 2026, an estimated $270K.
  • CytomX Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2440 holding.
  • Dimensional Fund Advisors first reported a position in CytomX Therapeutics in Q4 2018 and has held it in 23 quarters since.
  • Dimensional Fund Advisors's CytomX Therapeutics position peaked at $9.07M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.